See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bristol Myers Squibb Company (BMY) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb Company (BMY) - free report >>
Image: Bigstock
Bayer to Buy Monsanto for $62B to Boost Agriculture Portfolio
Bayer AG (BAYRY - Free Report) announced that it will acquire all issued and outstanding shares of the common stock of Monsanto Company at $122 per share in an aggregate all-cash offer worth $62 billion.
The company will use a combination of debt and equity to finance the transaction. Equity, which represents approximately 25% of the deal value, will be raised primarily via a rights offering.
The combined business is expected to provide accretion to Bayer’s core earnings in the mid-single-digit percentage in the first full year of the closing of the transaction, followed by double-digit percentage growth thereafter. Moreover, Bayer expects annual earnings contributions of around $1.5 billion from synergies after three years, as well as additional future benefits from integrated offerings.
The transaction is expected to bring together leading platforms like Seeds & Traits, Crop Protection, Biologics, and Digital Farming. The combined business will benefit from Monsanto’s Seeds & Traits and Bayer’s Crop Protection products across a comprehensive range of indications and crops. The transaction will also create attractive opportunities for the employees of both companies.
We remind investors that last week, Monsanto disclosed that it had received an unsolicited, non-binding proposal from Bayer for a potential acquisition, subject to due diligence, regulatory approvals and other conditions.
Currently, both Bayer and Monsanto carry a Zacks Rank #3 (Hold). A couple of better-ranked stock in the health care sector are Bristol-Myers Squibb Company (BMY - Free Report) and Pfizer Inc. (PFE - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>